FDA extends denecimig review: Novo Nordisk stock loses 1.02 percent
Published on 10/06/2026 at 14:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock was trading at EUR 33.09 at Lang & Schwarz on October 6, 2026 at 2:19 p.m. CEST, down 1.02 percent from the EUR 33.43 prior close. The latest company update puts denecimig's US regulatory path at the center of the story after the FDA extended its review because of manufacturing facility remediation.
FDA delay shifts the timetable
According to Nasdaq on October 2, 2026, the FDA said ongoing facility remediation activities caused the extension of its denecimig review. Novo said the agency's feedback concerned the manufacturing site and did not change its 2026 financial outlook.
The company still aims to launch denecimig in the United States in the first half of 2027, pending a regulatory decision. The key investor distinction is that the latest update centers on production readiness rather than the clinical development program.
Oral pipeline gets a new asset
GlobeNewswire reported on September 29, 2026 that Novo Nordisk agreed to license HRS-1596 from Hengrui Pharma. The phase 1-ready oral GLP-1 and GIP candidate carries potential deal value of up to USD 2.6 billion, including a USD 300.0 million upfront payment.
The agreement broadens Novo's oral obesity pipeline, but the total value depends on development, regulatory and commercial milestones. The transaction is expected to close in the fourth quarter of 2026, subject to customary conditions.
Wegovy data add a second signal
In a September 30, 2026 release, Novo Nordisk said real-world OCTANE data showed an average 4.10 percent weight loss after three months among people switching from injectable treatments to the Wegovy pill. The release also said 40.70 percent achieved at least 5.00 percent weight loss.
Those results do not remove the regulatory execution issue around denecimig, but they add a current operating datapoint to the wider oral-treatment strategy. The combination gives the stock two distinct near-term reference points: regulatory timing and evidence for tablet-based weight management.
November results set the next date
Novo Nordisk's investor calendar sets November 4, 2026, at 7:30 a.m. CEST for results covering the first three quarters of 2026, according to Novo Nordisk. That release should provide the next dated test of the 2026 outlook alongside updates on the pipeline.
The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.
Novo Nordisk stock facts
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Ticker: Novo-B
- Primary exchange: Nasdaq Copenhagen
- Price Lang & Schwarz as of October 6, 2026, 2:19 p.m. CEST: EUR 33.09
- Change versus prior close: minus 1.02 percent
- Prior close Lang & Schwarz September 5, 2026: EUR 33.43
- Sector / Industry: Healthcare / Drug Manufacturers - General
